193 related articles for article (PubMed ID: 15960553)
1. Remission from depression : a review of venlafaxine clinical and economic evidence.
Han D; Wang EC
Pharmacoeconomics; 2005; 23(6):567-81. PubMed ID: 15960553
[TBL] [Abstract][Full Text] [Related]
2. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs.
Doyle JJ; Casciano J; Arikian S; Tarride JE; Gonzalez MA; Casciano R
Value Health; 2001; 4(1):16-31. PubMed ID: 11704969
[TBL] [Abstract][Full Text] [Related]
3. The pharmacoeconomics of venlafaxine in depression.
Morrow TJ
Am J Manag Care; 2001 Sep; 7(11 Suppl):S386-92. PubMed ID: 11570029
[TBL] [Abstract][Full Text] [Related]
4. Assessment of Canadian provincial expenditures in depressed patients treated with venlafaxine XR versus SSRIs: the APEX Study.
Monfared AA; Han D; Sheehy O; Bexton B; Lelorier J
Curr Med Res Opin; 2006 Jan; 22(1):83-94. PubMed ID: 16393434
[TBL] [Abstract][Full Text] [Related]
5. Pharmacoeconomic analysis of venlafaxine in the treatment of major depressive disorder.
Einarson TR; Addis A; Iskedjian M
Pharmacoeconomics; 1997 Aug; 12(2 Pt 2):286-96. PubMed ID: 10170453
[TBL] [Abstract][Full Text] [Related]
6. A budget-impact and cost-effectiveness model for second-line treatment of major depression.
Malone DC
J Manag Care Pharm; 2007 Jul; 13(6 Suppl A):S8-18. PubMed ID: 17874482
[TBL] [Abstract][Full Text] [Related]
7. Medical resource use and cost of venlafaxine or tricyclic antidepressant therapy. Following selective serotonin reuptake inhibitor therapy for depression.
Griffiths RI; Sullivan EM; Frank RG; Strauss MJ; Herbert RJ; Clouse J; Goldman HH
Pharmacoeconomics; 1999 May; 15(5):495-505. PubMed ID: 10537966
[TBL] [Abstract][Full Text] [Related]
8. Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major depressive disorder.
Trivedi MH; Wan GJ; Mallick R; Chen J; Casciano R; Geissler EC; Panish JM
J Clin Psychopharmacol; 2004 Oct; 24(5):497-506. PubMed ID: 15349005
[TBL] [Abstract][Full Text] [Related]
9. Switching to sertraline or venlafaxine after failure of SSRIs treatment in major depressive disorder: an economic evaluation of the STAR*D trial.
Leelahanaj T
J Med Assoc Thai; 2012 May; 95 Suppl 5():S29-37. PubMed ID: 22934442
[TBL] [Abstract][Full Text] [Related]
10. Economic evaluation of duloxetine versus serotonin selective reuptake inhibitors and venlafaxine XR in treating major depressive disorder in Scotland.
Benedict A; Arellano J; De Cock E; Baird J
J Affect Disord; 2010 Jan; 120(1-3):94-104. PubMed ID: 19497623
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of venlafaxine for the treatment of major depression in hospitalized patients.
Priest RG
Clin Ther; 1996; 18(2):347-58; discussion 302. PubMed ID: 8733994
[TBL] [Abstract][Full Text] [Related]
12. Escitalopram: a pharmacoeconomic review of its use in depression.
Croom KF; Plosker GL
Pharmacoeconomics; 2003; 21(16):1185-209. PubMed ID: 14594439
[TBL] [Abstract][Full Text] [Related]
13. A cost-effectiveness model of escitalopram, citalopram,and venlafaxine as first-line treatment for major depressive disorder in Belgium.
Demyttenaere K; Hemels ME; Hudry J; Annemans L
Clin Ther; 2005 Jan; 27(1):111-24. PubMed ID: 15763612
[TBL] [Abstract][Full Text] [Related]
14. A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care.
Sørensen J; Stage KB; Damsbo N; Le Lay A; Hemels ME
Nord J Psychiatry; 2007; 61(2):100-8. PubMed ID: 17454724
[TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness of venlafaxine compared with generic fluoxetine or generic amitriptyline in major depressive disorder in the UK.
Lenox-Smith A; Greenstreet L; Burslem K; Knight C
Clin Drug Investig; 2009; 29(3):173-84. PubMed ID: 19243210
[TBL] [Abstract][Full Text] [Related]
16. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data.
Wade AG; Fernández JL; François C; Hansen K; Danchenko N; Despiegel N
Pharmacoeconomics; 2008; 26(11):969-81. PubMed ID: 18850765
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness evaluation in Sweden of escitalopram compared with venlafaxine extended-release as first-line treatment in major depressive disorder.
Nordström G; Danchenko N; Despiegel N; Marteau F
Value Health; 2012; 15(2):231-9. PubMed ID: 22433753
[TBL] [Abstract][Full Text] [Related]
18. A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK.
Wade AG; Toumi I; Hemels ME
Curr Med Res Opin; 2005 Apr; 21(4):631-42. PubMed ID: 15899113
[TBL] [Abstract][Full Text] [Related]
19. Re-evaluation of the efficacy and tolerability of venlafaxine vs SSRI: meta-analysis.
Weinmann S; Becker T; Koesters M
Psychopharmacology (Berl); 2008 Mar; 196(4):511-20; discussion 521-2. PubMed ID: 17955213
[TBL] [Abstract][Full Text] [Related]
20. Healthcare expenditure in severely depressed patients treated with escitalopram, generic SSRIs or venlafaxine in the UK.
Wade AG; Saragoussi D; Despiégel N; François C; Guelfucci F; Toumi M
Curr Med Res Opin; 2010 May; 26(5):1161-70. PubMed ID: 20297951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
